pen-221
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 8, 2016 (NCT02936323)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Somatostatin receptor 2INHIBITOR
SSTR2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- emtansine
Oral
No
Parenteral
No
Topical
No
Also known as
- pen-221
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02936323 | Phase 1/Phase 2 (Phase 2) | Dec 8, 2016 | Harvard University, Tarveda Therapeutics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Tarveda Therapeutics | For profit | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1